Skip to content
sellModerate cluster of 410b5-1 plan

Robert I Blum sold $7.3M of CYTK

President & CEO at CYTOKINETICS INC. 105,426 shares at an average of $69.62, traded Sep 14, 2026, filed Sep 15, 2026.

Warning score
40
Value
$7.3M
105,426 shares
Holdings after
0
-27% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet

Score components

  • Role
    CEO
    +25
  • Trade size
    $7.3M at market
    +25
  • Share of holdings sold
    Sold 27% of holdings
    +10
  • Cluster
    4 insiders selling within 14 days
    +15
  • Exercise and sell
    Shares came from an option exercise in the same filing
    -15
  • 10b5-1 plan
    Pre-scheduled under a 10b5-1 plan
    -20

What happened after comparable sells

Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.

Price around the trade, and since

From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.

CYTKOct 9, 2026 · close 62.91
Since filing Sep 15, 2026: -9.2%SPY +3.1% · excess -12.3%

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™

Rows in this filing

Every transaction in Form 4 0001061983-26-000094, as filed. Open on EDGAR

DateTransactionSharesPriceValueHoldings afterFiled
Sep 14, 2026MOption exercise
Common Stock10b5-1
+7,500$10.60$80k385,32026 d ago
Sep 14, 2026SOpen-market sale
Common Stock10b5-1
-7,500$73.44$551k377,82026 d ago
Sep 14, 2026GGift
Common Stock10b5-1
-1,350$0.00$0376,47026 d ago
Sep 14, 2026GGift
Common Stock10b5-1
-97,926$0.00$0278,54426 d ago
Sep 14, 2026GGift
Common Stockindirect: by Trust 3. Beneficial Ownership Disclaimed.10b5-1
+97,926$0.00$097,92626 d ago
Sep 15, 2026SOpen-market sale
Common Stockindirect: by Trust 3. Beneficial Ownership Disclaimed.10b5-1
-97,926$69.33$6.8M026 d ago
Sep 14, 2026MOption exercise
Non-Qualified Stock Option (Right to Buy)derivative10b5-1
-7,500$0.00$0156,74526 d ago

Related signals

Other insiders at CYTOKINETICS INC and this insider’s other filings.

ScoreCompanyInsiderValueHoldingsFiled
0Weak
CYTKsell 210b5-1
CYTOKINETICS INC
Fady Ibraham Malik
EVP Research & Development
$215k
3,500 shares
-2%
23Weak
CYTKsell 310b5-1
CYTOKINETICS INC
Robert I Blum
President & CEO
$491k
7,500 shares
-3%
8Weak
CYTKsell 310b5-1
CYTOKINETICS INC
Fady Ibraham Malik
EVP Research & Development
$239k
3,500 shares
-2%
23Weak
CYTKsell 410b5-1
CYTOKINETICS INC
Robert E Landry
director
$72k
1,000 shares
-11%
18Weak
CYTKsell 410b5-1
CYTOKINETICS INC
Robert E Landry
director
$75k
1,000 shares
-10%
8Weak
CYTKsell 410b5-1
CYTOKINETICS INC
Fady Ibraham Malik
EVP Research & Development
$264k
3,500 shares
-2%
35Weak
CYTKsell 410b5-1
CYTOKINETICS INC
B Lynne Parshall
director
$357k
5,000 shares
-32%
40Moderate
CYTKsell 310b5-1
CYTOKINETICS INC
Robert I Blum
President & CEO
$611k
15,000 shares
-3%
4Weak
CYTKsell 410b5-1
CYTOKINETICS INC
Fady Ibraham Malik
EVP Research & Development
$87k
2,000 shares
-1%
45Moderate
CYTKsell 410b5-1
CYTOKINETICS INC
Robert I Blum
President & CEO
$1.1M
25,000 shares
-7%

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

Robert I Blum sold $7.3M of CYTK | InsiderTell